The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis

• DOI: 10.4103/0301-4738.27948
• Publication Date: 2009-09-30T14:19:11Z
• Authors: Peykan Türkçüoglu; Tamer Demir; Ahmet Gödekmerdan; Mehmet Balbaba; Fulya Ilhan; Nesrin Demir
• Keywords: Male; experimental autoimmune uveitis; Anti-Inflammatory Agents; Autoimmune Diseases; Cyclosporine A; 03 medical and health sciences; 0302 clinical medicine; Animals; Arrestin; Tumor Necrosis Factor-alpha; Antibodies, Monoclonal; RE1-994; Infliximab; Recombinant Proteins; Interleukin-10; Rats; 3. Good health; Ophthalmology; Disease Models, Animal; Treatment Outcome; Rats, Inbred Lew; Cyclosporine; Cytokines; infliximab; Biomarkers; Immunosuppressive Agents; Injections, Intraperitoneal; recombinant IL-10; Follow-Up Studies

To identify the effect of infliximab, cyclosporine A and recombinant IL-10 in experimental autoimmune uveitis.Sixty male rats were assigned to five groups 12 each. All (except control group) administered 30 microg retinal-S antigen intraperitoneally. On 14th day, after confirmation uveitis with histopathological study, daily injection was given treatment group physiological serum uveitis-induced placebo groups. In infliximab group, on 14th, 15th, 17th, 19th 21st days. three doses four hours a half before eight administration. day all sacrificed vitreous cytokine levels (IL-1, IL-6, IL-8 TNF-alpha) studied ELISA.In groups, IL-6 significantly lower than group. Compared there no significant difference respect TNF-alpha group; The drugs used did not differ their effects levels.Cyclosporine A, reduce cytokines levels. Among these drugs, IL-10, which is still its phase, might be considered as new therapeutic agent.